title: Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle.
authors.affiliation: Department of Public Health and Epidemiology, University of Birmingham, Birmingham B15 2TT. r.s.taylor@bham.ac.uk
authors.forename: R S
authors.initials: RS
authors.lastname: Taylor
authors.forename: M F
authors.initials: MF
authors.lastname: Drummond
authors.forename: G
authors.initials: G
authors.lastname: Salkeld
authors.forename: S D
authors.initials: SD
authors.lastname: Sullivan
mesh_terms: D003219:Confidentiality; D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000191:economics* / Q000331:legislation & jurisprudence; D016527:Drug Costs; D005060:Europe; D006801:Humans; D007391:International Cooperation; D008004:Licensure; D012051:Reimbursement Mechanisms; D014481:United States